Previous 10 | Next 10 |
NovoCure (NVCR): Q1 GAAP EPS of -$0.04 misses by $0.06.Revenue of $134.7M (+32.3% Y/Y) misses by $3.41M.There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.Press Release For further details see: ...
Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size Novocure (NASDAQ: NVCR) today reported...
NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $138.11M (+35.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten re...
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also...
On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device ...
Novocure (NASDAQ: NVCR) hasn't exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this Motley Fool Live video recorded on April 14, 2021 , Motley ...
Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...
NovoCure continues to build out its product suite. The company is pivoting towards new indications which greatly expands the overall market. I think further expansion of its addressable market especially into non-small cell lung cancer should lead to an acquisition. For furt...
Novocure (NASDAQ: NVCR) has been on a tremendous run -- up 17 times over the last five years -- leaving many investors thinking that they missed the boat. But in investing, winners keep on winning. Recent news in the lung cancer treatment area for Novocure's Optune, a wearab...
Yesterday, Novocure's stock price made a huge jump of 50% because of an update of its LUNAR study. We look at the history of the company and the key people. Novocure already has 3 FDA approvals, 2 for glioblastoma and 1 for mesothelioma, but its total addressable market is much bi...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...